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Abstract
Research has shown that RNA virus populations are highly variable, most likely due to low fidelity replication of RNA
genomes. It is generally assumed that populations of DNA viruses will be less complex and show reduced variability when
compared to RNA viruses. Here, we describe the use of high throughput sequencing for a genome wide study of viral
populations from urine samples of neonates with congenital human cytomegalovirus (HCMV) infections. We show that
HCMV intrahost genomic variability, both at the nucleotide and amino acid level, is comparable to many RNA viruses,
including HIV. Within intrahost populations, we find evidence of selective sweeps that may have resulted from immune-
mediated mechanisms. Similarly, genome wide, population genetic analyses suggest that positive selection has contributed
to the divergence of the HCMV species from its most recent ancestor. These data provide evidence that HCMV, a virus with a
large dsDNA genome, exists as a complex mixture of genome types in humans and offer insights into the evolution of the
virus.
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Introduction
Human cytomegalovirus (HCMV) is member of the b-
herpesvirus family. It is a ubiquitous, opportunistic pathogen,
with seroprevalence of 30–90% in the United States [1]. In
healthy individuals, primary HCMV infection is usually asymp-
tomatic or can result in a mild febrile illness. However, infection
persists throughout the life of the host. HCMV infections can be
problematic for those with compromised or immature immune
systems. For example, congenital HCMV infection is the leading
cause of birth defects resulting from an infectious agent, affecting
about 0.5% of all live births [2] and costing the U.S. Health care
system ,$2 billion annually [3]. Long term sequelae of congenital
HCMV infections include deafness, blindness and/or mental
disability [4].
HCMV contains the largest genome of any human virus with a
dsDNA genome of ,236 kilobase pairs [5]. Sequence analysis
predicts that the genome encodes approximately 164 open
readings frames (ORFs) [6]. The genome contains two unique
regions (termed UL and US) that are flanked by repeats (termed RL
and RS) both internally and terminally, although the internal RL
region is not present in clinical isolates or low passage strains.
Previous work with cell culture passed virus has shown that the
genome of HCMV displays sequence variability. For example, the
laboratory strain AD169 is a highly passaged, attenuated variant.
The genome of AD169 as compared to low passage strains has an
approximately 15 kb deletion which encodes an additional 19 or
22 open ORFs, referred to as the UL/b’ region [6,7,8].
Approximately 20 ORFs of HCMV have been shown to exhibit
nucleotide variability when sequenced from infected hosts
[9,10,11,12,13,14,15,16,17,18,19]. These studies have often fo-
cused on the variability of ORFs encoding envelope glycoproteins
or ORFs of UL/b’, which are thought to be important for
pathogenesis. As examples, UL55 and UL73, encoding the gB and
gN glycoproteins, respectively, commonly exist as one of 4
genotypes, with less common genotypes also identified [19,20].
In the UL/b’ region, UL144, encoding a TNF-a receptor [21],
and UL146 and UL147, encoding a-chemokines [22], also show
significant variability among hosts [9,14,23,24,25].
Although it is known that HCMV is polymorphic among hosts,
the source of the variability remains unresolved. There are at least
two possibilities to explain the observation. The first is that de novo
mutations arise upon introduction into a new host, resulting in a
unique strain for each individual. The second possibility is that
multiple HCMV genotypes exist within each host, and infection
into a new host represents a selection event whereby a new
dominant genotype is selected for and detected in subsequent
assays. In support of this model, others have found evidence of
mixed genotype populations at the few loci examined. Mixed
populations have been observed when measuring gB genotypes
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for other ORFs, such as gN, gO, gH, gL, UL139, and UL146
[31,32,33,34,35,36,37]. Furthermore, mixed populations have
been shown in a range of patient populations, including
immunocompetent, asymptomatic adults [31] and have been
shown at multiple loci simultaneously [33]. While definitive
relationships between genotypes and diseases are lacking, there is
mounting evidence that mixed genotype infections serve as
markers of severe or prolonged complications from HCMV
infections [26,27,29,30,34,36]. A shortcoming of the mixed
genotype studies has been limited coverage of the HCMV
genome. To our knowledge, less than 5% of the HCMV genome
has been sequenced from clinical specimens in these types of
studies (Figure S1). Thus, a remaining question is whether HCMV
diversity is limited to a subset of ORFs or is found throughout the
genome.
From earlier studies, it appears that HCMV may exist as a
mixture of genotypes. Due to limitations of previous technology, it
was unrealistic to study mixed HCMV populations to great depth
or sequence the HCMV genome to high coverage. To address
these shortcomings, we have adapted high throughput sequencing
to sample many members of the HCMV genomic population,
rather than just a dominant member. With the improved output of
next generation sequencing, we were able to take a genome wide
approach and sequence thousands of HCMV genome equivalents
from each patient sample. Here we sampled the HCMV genomic
populations present in urine samples collected from three
congenitally infected newborns. These data reveal a high level of
intrahost variability and offer strong evidence that HCMV exists
as a complex mixture of variants. We also found evidence of
selection at both the intrahost and interhost levels, highlighting
evolutionary forces that shape the HCMV genome. These results
greatly improve our understanding of the structure of HCMV
populations in humans, and have important implications for the
study of DNA viruses.
Results
Development of sequence methodology and error
filtering protocol
In clinical samples, HCMV DNA represents a very low
proportion of the total DNA. Thus, direct sequencing would yield
a low depth of the HCMV population with human DNA being a
major source of contaminant. Because there is homology between
the human and HCMV genomes [38,39], this contaminant would
be problematic in downstream sequence analyses. We developed a
series of approximately 70 long range, overlapping PCR reactions
to selectively amplify the entire HCMV genome. However, PCR
amplification can introduce errors of its own, which could be
misinterpreted as polymorphisms. To assess the error associated
with sample processing, we resequenced BACs that contained the
genomes of the HCMV strains AD169 and Toledo. The BACs
have been shotgun sequenced to a 10X depth [40], producing
reliable reference sequences for these purposes.
The BAC DNA was amplified through a series of PCR reactions
and sequenced on the Illumina GA II paired end platform. The
sequence output was equivalent to ,220 genomes per strain
(Table 1). The sequence reads were aligned to the appropriate
reference sequence and the alignments were analyzed for errors.
We assumed that all mismatches between the sequencing reads
and the reference sequence were errors introduced by either PCR
or sequencing. This assumption is most likely conservative because
there is the possibility that variants were created by propagating
the BACs in E. coli or that errors could be present in the reference
sequences. The alignment data contained in the pileup file was
then processed with a variant filtering program. The variant
filtering program only outputs variants that are above threshold
values for basecall quality, mapping quality, depth at the position,
number of occurrences of the same variant and frequency of the
variant in the data. The thresholds used were: basecall quality
$30, mapping quality $89, depth $15, number of occurrences
$3, and frequency $.019. The basecall quality and mapping
quality values are used to filter nucleotides with low confidence
from sequencing or from reads that align with low confidence,
respectively. Depth, number of occurrences of variant and
frequency are used to remove likely errors because random errors
(from either sample amplification or sequencing) have the highest
likelihood of occurring as singletons and doubletons (1 or 2
occurrences). These threshold values were chosen by training the
filtering program with BAC resequencing data. The resequencing
data from AD169 and Toledo were mixed in various ratios to
model a mixed population. The filtering thresholds were selected
to increase specificity of detecting true variants; however, they
carry a penalty of reducing sensitivity and underestimating the
amount of variants in the sample (Table S1). The number of false
positives remains low at various depths and mixtures of the
sequences. We did not find evidence of amplification-induced
skewing of variant frequencies. Further discussion of analysis of
error can be found under Materials and Methods and Supple-
mental Information.
High throughput sequencing of clinical populations
We sampled HCMV genomic populations present in the urine
collected from 3 HCMV-positive neonates within 2 weeks of birth
(identified as U01, U04, and U33). The entire HCMV genome
was amplified as discussed above. The PCR reactions and amount
of template DNA were identical between the BAC resequencing
and the clinical sequencing. Therefore, the error filtering protocol
developed through BAC resequencing can be applied to the
clinical sequence data. From clinical sequencing, .300 megabases
of output per sample yielded an average depth of 1843 genome
equivalents and an average genome coverage of 97.8% for the 3
samples (Table 1 and Figure S3).
Initially, the sequence reads from the urine samples were
aligned to the sequence of the Merlin strain, which was used as the
HCMV reference genome (Ref Seq ID: NC_006273). From the
Author Summary
Human Cytomegalovirus (HCMV) is a dsDNA virus that is
the leading source of birth defects associated with an
infectious agent. There is currently no effective HCMV
vaccine and few treatment strategies for congenital
infections exist. Thus, a better understanding of HCMV
infections is warranted. Limited data has shown that HCMV
exists as a mixture of a few genotypes in human hosts.
Here, we describe our use of high throughput sequencing
to study the extent of genome wide variability within
HCMV infections sampled from congenital infections.
Surprisingly, we find that HCMV populations are as variable
as quasispecies RNA viruses; it is commonly believed that
DNA viruses are more genetically stable than RNA viruses,
and thus produce homogenous populations. Additionally,
we find evidence of evolutionary pressures acting on the
HCMV genome, both within and among populations.
These results provide the first evidence that diversity of
DNA virus populations can be comparable to that of RNA
virus populations.
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4 single nucleotide variants (range: 11289–15709)
were detected per viral population. Variants segregated into
clusters at frequencies #.1 or $.9 (Figure 1). Variants with
frequency #.1 represent on average 73% (Range 67%–78%) of
the total and variants with frequency $.9 represent 20% (Range:
16%–24%). From these data, we conclude that the high frequency
variants result from the major alleles found in the viral population
while the low frequency variants result from the minor alleles.
Generation of a sample specific genome type
To study HCMV intrahost variability, we defined the major
HCMV genome type of each sample and called intrahost variants
from this reference genome type (Figure S4). A genome type is the
genome wide analog of a genotype [41,42,43]. The major genome
type contains the major allele found at every position of the
genome. Thus, any variants from this genome type represent
minor alleles or minor variants. It should be noted that the
genome type may not represent any single DNA molecule in the
viral population. Rather, the major genome type is a computa-
tional tool that allows for the detection of minor variants in the
population, and every position of the genome in this analysis and
all later analyses are treated independently (i.e. unlinked).
To define the major genome type, output from an initial
alignment to Merlin was used to detect variants with frequencies
.0.5 (Figure S4). These variants were interpreted to represent the
major allele of the sample at each position. Variants were
incorporated into the reference sequence to create an initial
sample-specific genome type. Reads that did not initially align
were used as substrate for de novo contiguous sequence (contigs)
assembly. The contigs were aligned to the initial sample-specific
genome type and incorporated into the genome if sequence
identity was found. This modified genome type was used to serve
as the reference sequence for another round of alignment of the
sequencing reads and subsequent incorporation of high frequency
variants and assembly of contigs onto the sample specific genome
type. This process of constructing a sample-specific genome type
was repeated until no additional reads were aligned between
rounds of building the genome type (usually 4 rounds). At the end
of the process, a single sequence was produced that represents the
sample-specific genome type and contains the major nucleotide of
the sample at every position of the genome. Lastly, the sequence
reads were aligned to this genome type, and the alignment was
used to call intrahost variants and to quantify intrahost diversity.
Intrahost HCMV populations are diverse
Intrahost variants were classified by ORF to quantify both
intergenic and genome wide variability (Table 2, Table S3 and
Figure 2). There were .8,500 intrahost variants in each sampled
population. (Range: 8,562–13,335) (Table 2), and ,91% of the
variants were present at frequencies ,0.1. We compared the levels
of variants from clinical sequencing and BAC resequencing to
determine the level of false positives or errors within the clinical
data. The false positive rate was reduced to 6.7% with filtering
(Figure S2).
Our initial analysis of the intrahost variability focused on the
ORFs encoding the glycoproteins, gB (UL55) and gN (UL73).
These ORFs have well defined genotype classifications [19,20]
and previous studies have shown mixed genotype populations for
these ORFs [27,44]. Full genotypes cannot be determined using
short read sequencing because linkage information is lost between
regions larger than a sequence read (i.e. 72 nt in this work). We
analyzed the presence and frequency of amino acid variants that
are markers of gB or gN genotypes as a substitute for full-length
genotype data. For example, at position 181 of gB, a lysine is
unique to the gB2 genotype and an arginine is unique to gB3 [19].
K181 or R181 within gB serves as a marker of these two
genotypes. The frequency of these markers is the inferred
Table 1. Sequence output of high throughput sequencing experiments.
Source
1 Type Reads % Aligned Reads Sequence Output (Mb) Depth
2 Coverage
3
AD169 BAC 774,803 94.9% 51.1 218 98.7%
Toledo BAC 720,120 96.0% 47.5 226 96.8%
U01 Urine 2,444,677 74.9% 337.4 1493 97.0%
U04 Urine 3,395,157 74.7% 468.5 1990 98.7%
U33 Urine 3,490,699 80.7% 481.7 2046 97.7%
1Source was BAC DNA encoding the AD169 or Toledo genome, or urine samples collected from neonates (,2 weeks from birth) with congenital HCMV infections.
2Depth is the average number of reads that cover each position of the genome.
3Coverage is expressed as percentage of the genome for which sequence data was generated. For AD169 and Toledo resequencing, the published sequence was used
to calculate coverage. For clinical material sequencing, the coverage is estimated by using the Merlin strain reference genome.
doi:10.1371/journal.ppat.1001344.t001
Figure 1. Single nucleotide variant frequencies of HCMV
populations segregate into low and high frequency classes.
Histogram of binned variant frequencies within three HCMV popula-
tions sampled from urine samples. The graphs are labeled according to
patient sample (U01, U04, and U33). The variants have been filtered to
reduce errors, thereby eliminating variants of frequency ,1.9%. See
Figure S2 for analysis of the effectiveness of the error filtering algorithm.
doi:10.1371/journal.ppat.1001344.g001
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genotype populations existed for the gB (UL55) and gN (UL73) loci
in congenitally infected infants in agreement with previous studies
[27,44] (Table 3). However, these data represent ,0.5% of the
HCMV genome, and led us to determine whether evidence of
mixed populations exists throughout the genome.
To further define the intrahost diversity of HCMV populations,
we first analyzed the genome wide data at the nucleotide level. We
used the measures of nucleotide diversity (p) [45] and mean
diversity [46], which were calculated as averages for all ORFs of
the HCMV genome (Tables 2 and S3 and Figure 2). p is the
average pairwise distance of sequences in the population, and
mean diversity is the percentage of variant sequence within the
population. The genome wide average for p for the 3 samples was
0.22% (Range: 0.18%–0.25%). As a point of comparison, this
value is similar to the genome wide p for HIV [47] and the single
ORF intrahost p of other RNA viruses, such as hepatitis C,
dengue, and West Nile [48,49,50,51] (Figure 3 and Table S4).
Single ORF intrahost p was as high as 0.64% for HCMV. The
HCMV genome wide mean diversity was 0.20% (Range: 0.17%–
0.22) and is similar to that of HIV-1 and dengue virus [46,50].
Figure 2 also reveals that intrahost diversity was not limited to a
few loci but was found within most ORFs. The ORFs encoding gB
(UL55) and gN (UL73) were in the 32
nd and 20
th percentile for
ORF intrahost diversity, respectively, (Table S3) and do not reflect
the genome wide diversity. Therefore, HCMV populations are
variable and using unbiased, genome wide data for studying that
diversity offers an advantage over previous techniques that have
focused on a limited set of loci.
We grouped ORFs by gene product function or expression
kinetics using the classification of Sylwester et al. [52] to further
investigate the patterns of intrahost diversity (Figures 4 and S6).
However, there was considerable variation of sequencing depth of
some ORFs (Table S3) raising the possibility that uneven
sequencing depths could influence this analysis of diversity.
Indeed, there was a correlation between nucleotide diversity of
an ORF and the extremes of sequencing depth (Figures S5A). To
reduce the influence of excessive depth on the analysis, we focused
on ORFs with sequencing depths between 15 and 1200 (n=338)
(Figure S5B). In this range, the influence of depth on nucleotide
diversity will be ,.01%, which is approximately the level of noise
generated from errors in BAC resequencing. After selecting for
ORFs sequenced to depths within this range, we did not observe
significant difference nucleotide diversity across expression class.
However, we did find a statistically significant association between
ORF function and intrahost nucleotide diversity (p ,.0001)
(Figure 4 and S6). ORFs encoding glycoproteins showed a reduced
level of intrahost nucleotide diversity. This latter result was
Figure 2. Intrahost nucleotide diversity was detected in most
ORFs of the HCMV genome. Intrahost nucleotide diversity (p) was
plotted for each ORF of the HCMV genome based on high throughput
sequence data of clinical samples from three patients: U01, U04, and
U33. The ORFs are listed in layout of the standard HCMV genome from
59 to 39. See Table S3 for a tabular representation of these data. Due to
space constraints, not all ORFs are named on the plot. The major
divisions of the HCMV genome are shown below the graph.
doi:10.1371/journal.ppat.1001344.g002
Table 2. Intrahost diversity of hcmv populations in clinical samples: genome wide averages.
Sample Variants
1 p
2 (%) Mean Diversity (%) pAA
3 (%) pSYN
3 (%) Variable AA Sites
4 (%)
U01 8,562 0.18 0.17 0.14 0.04 12.3
U04 13,335 0.25 0.22 0.15 0.05 13.8
U33 10,318 0.22 0.21 0.16 0.06 14.0
1Variants are the total intrahost single nucleotide variants.
2p is the nucleotide diversity as calculated using the formula of Nei and Li [45].
3pAA is the intrahost amino acid diversity and pSYN is the diversity of all synonymous mutations. Both were calculated in the same way as p but only using
nonsynonymous or synonymous mutations, respectively.
4Variable AA Sites are the percentage of amino acid positions in which nonsynonymous intrahost variants were detected.
doi:10.1371/journal.ppat.1001344.t002
Table 3. Frequency of gB and gN genotype markers in high
throughput sequence data.
U01 U04 U33
gB
1 gB1 6.5% 2.9% 97.3%
gB2 91.1% 93.3% 2.7%
gB3 2.4% 3.8% -
gB4 ---
gN
1 gN1 9.8% - 3.7%
gN2 2.8% 100% 2.6%
gN3 5.8% - 4.3%
gN4a 78.8% - 89.4%
gN4b ---
gN4c 2.8% - -
1gB genotyping is based on [19], and gN genotyping is based on [20]. Unique
amino acid variants for each gB or gN genotype were used as markers of the
respective genotype. The frequency values of the markers in the sequenced
populations are listed in the table.
doi:10.1371/journal.ppat.1001344.t003
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analyzed in earlier studies of intrahost variability.
To confirm the results obtained via high throughput sequenc-
ing, we assayed for p and genotype distribution by clonal Sanger
sequencing of three highly variable ORFs in each patient sample.
We found that the major genotype detected in both methods is the
same (data not shown). Also, the values for p determined by both
high throughput and Sanger sequencing were generally similar for
each ORF (Table 4). Clonal Sanger sequencing of these ORFs
revealed a high density of unique genotypes in the clinical samples,
with as many as 13 unique genotypes from 20 clones. The Sanger
sequence data was also used to generate unrooted phylogenetic
trees (Figures 5 and S7). Within the trees, we have included major
genotype sequence data from the other patient samples in this
study to provide perspective on the diversity of the clones. In some
Sanger datasets, the diversity of clones could be explained by one
or two mutational steps from the major genotype (Figure 5A).
Other datasets revealed clones within a patient sample that were
more divergent than sequences among patient samples (Figure 5B).
This result could represent a highly mutagenic viral population, a
co-infection with two or more strains, mixtures of viral variants
from different compartments, or a combination of these
mechanisms. An interesting side note is that, in a single patient
sample, there is evidence for diversity from a few mutational
events (Figure 5C), and possible evidence of co-infections
(Figure 5D). Thus, the mechanism(s) that leads to the diversity
of HCMV populations may be complex.
Because the coding sequence of HCMV populations appeared
to be highly variable, we next investigated whether there were
differences in variability between coding and non-coding regions
of the genome. For this analysis, coding regions were defined as
protein coding sequences, and non-coding regions comprised the
remainder of the genome. Thus, the non-coding regions likely
contain functionally important sequences due to the inclusion of
regions such as the origin of replication, transcription factor
binding sites and miRNA sequences. Using these parameters, we
found that there was a statistically significant difference between
intrahost diversity of the coding and non-coding regions (Table 5).
The coding regions had higher nucleotide and mean diversity
values than the non-coding regions; however, the average
frequency of coding variants was significantly less than the average
frequency of non-coding variants. Although the differences in
values for these summary statistics are small, as seen in the U04
population, it should be noted that coding and non-coding variants
are interspersed across the genome. Thus, this proximity should
allow for statistical robustness and may reflect a fine-scale
mechanism regulating the amount and frequency of coding and
non-coding variants.
We next investigated the clinical HCMV populations at the
amino acid level. The average intrahost amino acid diversity (pAA)
was 0.18% (Table 2), which is comparable to RNA viruses such as
dengue and West Nile [48,50]. The diversity at nonsynonymous
sites (pAA) was ,3-fold higher than at synonymous sites (pSYN),
suggestive of a slight excess of nonsynonymous mutations within
the HCMV populations. The genome wide average for the
percentage of amino acid sites that exhibited intrahost variability
was 13.4% (Range: 12.3%–14.0%) (Table 2). This value reveals
the substantial variation in intrahost coding potential of HCMV
populations. Taken together, these data support a model of
HCMV existing as diverse populations at both the nucleotide and
amino acid levels. This result is novel for a large dsDNA virus,
which encodes a DNA polymerase with exonuclease activity [53].
Evidence of positive selection in HCMV intrahost
populations
Having found significant levels of intrahost variability, we felt it
was important to determine whether the patterns in variability
were the result of genetic drift (i.e. neutrality) or if selection could
explain the observed variant frequency patterns in the populations.
We applied the model of Nielsen et al [54] to detect selective
sweeps within the genome wide variant data. Selective sweeps are
caused by positive selection and result in reduced variability
around the region under selection [55,56]. Importantly, the test of
Nielsen et al is robust to demographic effects. This is a critical
function because the HCMV populations under study have most
likely undergone significant recent demographic changes, such as
population bottlenecks and expansions associated with primary
infection. The Nielsen approach is an outlier test that calculates
the likelihood of a selective sweep based on the distribution of
variant frequencies within a region as compared to the genome as
Figure 4. HCMV intrahost nucleotide diversity is significantly
correlated with ORF function. Intrahost nucleotide diversity was
calculated for each ORF of the HCMV genome. The ORFs were then
grouped by function and average nucleotide diversity was calculated
across all three patients. Error bars represent the 95% confidence
interval for the calculated mean. 1-factor ANOVA test for significance:
p ,0.0001.
doi:10.1371/journal.ppat.1001344.g004
Figure 3. HCMV intrahost diversity is similar to RNA viruses. A
logarithmic number line plotting nucleotide diversity for representative
RNA viruses is shown. West Nile virus (WNV), dengue virus (DENV) and
human immunodeficiency virus (HIV) were chosen because they exhibit
low, mid, and high levels of p, respectively, for RNA viruses. The HIV
values are from a whole genome sequencing study of 12 samples [47],
and the minimum (HIV Min) and maximum (HIV Max) values are shown.
HCMV Average is the genome wide average across patients for p and
HCMV Max is the maximum ORF value obtained from Illumina
sequencing. See Table S4 for a more thorough list of nucleotide
diversity values for RNA virus populations.
doi:10.1371/journal.ppat.1001344.g003
Genome Wide Variability of HCMV
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measure of this comparison, with higher CLR values indicating
the region is a more extreme outlier and thus, more likely a target
of positive selection. Applying the model of Nielsen et al to the
HCMV genome wide data, we identified an average of 9 ORFs
per population (Range: 2–15) under statistically significant positive
selection (Figures 6 and S8 and Table S5), including UL83 (pp65)
and UL123 (IE1). While there was no overlap between the positive
selected ORFs in the three samples, there was evidence of overlap
in protein function. For example, UL102 in the U01 sample and
UL105 in the U04 sample were targets of selective sweeps, and
protein products of both ORFs are subunits of the helicase-
Figure 5. Unrooted phylogenetic trees of HCMV populations show varying levels of diversity. Highly variable ORFs in the high
throughput sequencing dataset of each patient sample were selected for clonal Sanger sequencing. Unrooted phylogenetic trees were generated
from the data, and major genotype sequence data from the other patient samples in this study were included to provide perspective (shown in red
text). The trees from some datasets showed clones that were unique but closely related (5A, 5C). The clones from others datasets were more
divergent, such that divergence within a patient sample was larger than divergence between patient samples (5B, 5D). Examples of both patterns
could be seen at different ORFs from the same patient sample (5C, 5D). Phylogentic trees generated from all Sanger datasets can be seen in Figure
S7. Units for scale bars are substitutions per site.
doi:10.1371/journal.ppat.1001344.g005
Table 4. Intrahost nucleotide diversity as measured by two sequencing methods.
Patient Sample ORF p (Illumina)
1 p (Sanger)
2 Clones Sequenced
3 Unique Genotypes
3
U01 UL2 0.59% 0.50% 20 10
UL4 0.53% 0.51% 19 7
UL51 0.40% 0.33% 20 9
U04 UL117 0.64% 0.40% 19 9
UL15a 0.64% 0.58% 19 8
UL26 0.62% 0.52% 20 9
U33 UL48a 0.62% 0.52% 19 9
UL136 0.61% 0.48% 18 9
UL15a 0.57% 0.57% 20 13
1p (Illumina) is the nucleotide diversity calculated from Illumina high throughput sequence data.
2p (Sanger) is the nucleotide diversity calculated from clonal Sanger sequencing.
3The number of clones sequenced and unique genotypes refers to the Sanger sequencing data.
doi:10.1371/journal.ppat.1001344.t004
Genome Wide Variability of HCMV
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have either poorly defined or no known function.
Interhost HCMV variability and selection
The generation of HCMV sequence data from urine specimens
allowed for genome wide analysis of interhost polymorphisms across
clinical samples, as opposed to those observed in laboratory
passaged strains. For this analysis, polymorphisms were defined as
variants from the HCMV reference sequence with frequencies
.0.5, and are the same class of variants previously incorporated
into a sample specific genome type. By resequencing HCMV BACs,
we determined that the error rate for calling polymorphisms is
0.028%., i.e., ,65 erroneous polymorphisms are called within a
236,000 bp genome type (Table S2). On average, there were
,2600 polymorphisms per genome type resulting in an interhost
variability of 1.1% at either the nucleotide or amino acid level
(Table 6). Only 7.9% (612 of 7,780) of the nucleotide polymor-
phisms and 1.2% (25 of 2,129) of the amino acid polymorphisms
were common among the 3 samples. This result shows that most of
the polymorphisms are not only different between clinical
populations and a laboratory passaged strain (Merlin), but they
appear to be uniquely associated with the specific environments of
the viral populations. Thus, these findings are consistent with
previous work showing diversity of the HCMV species [5].
Next, we wanted to determine whether there is evidence of
selection within the interhost sequence data. Previously, single
Table 5. Distribution of intrahost variants in coding and non-coding regions of the HCMV genome.
U01 Non-coding Variant Sites Variants Length (bp) p
Mean
Diversity
Average Variant
Frequency
p value (Mean
Diversity)
1
p value
(Frequency)
2
1222 69544 48552 0.14% 0.12% 6.44%
Coding Variant Sites Variants Length (bp) p Mean
Diversity
Average Variant
Frequency
,.0001 ,.0001
7462 498257 187075 0.18% 0.19% 5.02%
U04 Non-coding Variant Sites Variants Length (bp) p Mean
Diversity
Average Variant
Frequency
p value (Mean
Diversity)
1
p value
(Frequency)
2
2430 115228 48521 0.24% 0.25% 5.44%
Coding Variant Sites Variants Length (bp) p Mean
Diversity
Average Variant
Frequency
,.0001 ,.0001
11152 797847 187117 0.25% 0.26% 4.50%
U33 Non-coding Variant Sites Variants Length (bp) p Mean
Diversity
Average Variant
Frequency
p value (Mean
Diversity)
1
p value
(Frequency)
2
1474 51079 48451 0.17% 0.13% 7.07%
Coding Variant Sites Variants Length (bp) p Mean
Diversity
Average Variant
Frequency
,.0001 ,.0001
9043 904298 186841 0.22% 0.27% 5.23%
1p value for a Z-test of proportions of the mean diversity of the non-coding and coding variants.
2p value for a two-tailed Mann-Whitney test for the distribution of variant frequencies of the
doi:10.1371/journal.ppat.1001344.t005
Figure 6. Selective Sweeps were detected within HCMV
intrahost populations. Intrahost variant data was processed with
the model of Nielsen et al and composite likelihood ratios (CLRs) were
calculated for 235 bp windows across the HCMV genome. CLRs are
measures of the probability of a selective sweep within a genomic
region. Simulations were run to determine the threshold values for
significance and these values are depicted as red, dashed lines across
the graphs (see Figure S8 for a presentation of the simulation data).
Each CLR above the threshold is considered significant and is indicative
of a selective sweep occurring within the window. See Table S5 for a
tabular presentation of ORFs located in statistically significant regions
and the corresponding CLR and p values.
doi:10.1371/journal.ppat.1001344.g006
Table 6. Interhost variability of hcmv populations in clinical
samples: genome wide averages.
Patient Polymorphisms p
1 dN/dS
2 pAA
3
U01 2,909 1.20% 0.10 1.05%
U04 2,347 0.97% 0.14 1.09%
U33 2,524 1.01% 0.14 1.23%
1p is the nucleotide diversity between the consensus sequence from each
clinical HCMV population and the HCMV reference sequence (Merlin) as
calculated using the formula of Nei and Li [45].
2dN/dS was calculated using the formula of Nei and Gojobori [73].
3pAA is the interhost amino acid diversity between clinical major genome type
and the HCMV reference sequence (Merlin). It is calculated with the same
formula as p but only nonsynonymous mutations are included.
doi:10.1371/journal.ppat.1001344.t006
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than 1 [57,58], suggestive of negative selection. Using the genomic
data, we calculated dN/dS values for all ORFs of the HCMV
genome and also calculated a genome wide average. In agreement
with previous studies [57,58], the genome wide average dN/dS
values were significantly below 1 (p ,0.0001, G-test) (Table 6,
Table S6 and Figure 7). Approximately 5% of ORFs exhibited
dN/dS values greater than 1, which is suggestive of positive
selection. To find patterns in the genome wide dN/dS values,
ORFs were classified according to protein product function and
expression kinetics (Figures 8 and S9). No significant association
was seen between dN/dS and expression kinetics, but a highly
significant association was observed between protein product
function and dN/dS (p=0.0002). Envelope proteins exhibited
elevated dN/dS values and DNA replication proteins showed low
dN/dS values (Figure 8).
We next used the McDonald-Kreitman (MK) test on the clinical
sequence data to further analyze selective pressures. The input
data for the MK test are the divergent (i.e. interspecies) nonsynon-
ymous (DN) and synonymous (DS) mutations and the polymorphic
(i.e. intraspecies) nonsynonymous (PN) and synonymous (PS)
mutations [59]. Due to the inclusion of both polymorphic and
divergent mutations, the MK test is a more sensitive test for
selection than the dN/dS statistic. A 2x2 contingency table of the
values is used to calculate significance of the mutational pattern
and the respective ratios provide information regarding the
direction of the test rejection. For example, positive selection is
generally regarded to result in a (DN/DS)/(PN/PS) ratio .1, while
negative selection results in a ratio ,1.
A genome wide MK test was performed using sequences of all
orthologous ORFs (n=160) from Merlin and the three clinical
samples with the inclusion of chimpanzee cytomegalovirus
(CCMV) as the outgroup. Approximately 65% (n=104) of ORFs
were scored as neutral in this test. ORFs yielding (DN/DS)/(PN/
PS) ratios significantly .1 were ,4-fold more frequent than ORFs
producing ratios significantly ,1 (n=45 and n=11, respectively)
(Table S7). This pattern could result from positive selection.
However, considering the statistically robust, non-neutral dN/dS
values, there is also widespread evidence of pervasive negative
selection. Taken together, the results suggest that positive selection
has driven the fixation of HCMV-specific mutations, and
contributed to the divergence of the HCMV and CCMV species.
However, demographic effects could also contribute to the
observed mutational patterns and cannot be completely ruled
out from these analyses, though considering inter-digitated
synonymous and nonsynonymous sites ought to allow for a robust
statistic.
Discussion
High throughput sequencing has dramatically increased the
number of genomes sequenced and is a useful tool for analyzing
populations present within various environments. Our work
represents the first use of high throughput sequencing technology
to study the intrahost genomic populations of a large DNA virus in
clinical samples. We observed substantial intrahost variability that
was found throughout the HCMV genome and found evidence of
selection both at the intrahost and interhost levels.
An unexpected finding of this study was that almost every ORF
of the HCMV genome showed some level of intrahost diversity in
the three populations that were sampled. Thus, these results are an
important extension of previous work that has revealed intrahost
diversity within a small number of ORFs, including gB and gN
[27,44]. However, the present data suggest that genotyping may
not be a reliable surrogate for measures of HCMV diversity in
clinical specimens. For example, the gB and gN genotype data in
Table 3 suggest that sample U01 is genetically the most diverse
and U04 is the least diverse. However, Table 2 shows the opposite
to be true. U01 is the least diverse and U04 is the most diverse for
HCMV on genome wide scales.
By quantitating variability using the measure of nucleotide
diversity, it can be seen how the intrahost diversity of HCMV is
comparable to those of RNA viruses, including HIV. The
similarity in values is striking considering the common assumption
Figure 7. A majority of ORFs appeared to be under negative
selection based on interhost dN/dS values. Interhost dN/dS were
plotted for each ORF of the HCMV genome based on high throughput
sequence data of clinical samples from three patients: U01, U04, and
U33. The ORFs are listed in layout of the standard HCMV genome from
left to right. See Table S6 for a tabular representation of these data. Due
to space constraints, not all ORFs are named on the plot. The major
divisions of the HCMV genome are shown below the graph.
doi:10.1371/journal.ppat.1001344.g007
Figure 8. HCMV interhost dN/dS is significantly correlated with
ORF function. Interhost dN/dS values were calculated for each ORF of
the HCMV genome. The ORFs were then grouped by function and
average interhost dN/dS was calculated across all three patients. Error
bars represent the 95% confidence interval for the calculated mean. 1-
factor ANOVA test for significance: p=0.0002.
doi:10.1371/journal.ppat.1001344.g008
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DNA viruses due to the lower replication fidelity of RNA genomes.
Thus, this work leads to a questioning of the source of the diversity
observed in HCMV populations. One possibility is the prevalence
of high mutation rates during replication of viral DNA genomes,
similar to RNA viruses. This possibility does not seem likely
considering that HCMV encodes a DNA polymerase with
proofreading activity [53]. A second possibility is low mutation
rates but high levels of replication, leading to an accumulation of
mutations. In support of this model, it is suspected that only a
single or very few virions cross the placenta to initiate a congenital
infection. At the time of collection (,2 weeks postnatally), the
samples contained ,10
7 HCMV genome copies per mL of urine
(data not shown). Thus, there had been many rounds of recent
replication within the new host before the populations were
sampled, which could lead to the accumulation of many variants
even with a low mutation rate. Alternatively, the diversity could
result from re-infection or co-infection. The phylogenetic trees of
select ORFs (Figure 5 and S7) suggest that some ORFs are highly
divergent from a central population of genotypes, which suggests
re/co-infection events. However, phylogenetic trees for other
ORFs reveal highly similar clones. More experiments are needed
to sort out these possibilities.
Although the source of diversity is currently unclear, the
existence of high intrahost diversity does lead to models of HCMV
evolution. Creation of de novo mutations is stochastic and most
likely occurs rarely, as suggested by the proofreading DNA
polymerase encoded by HCMV. A high level of standing or pre-
existing variation means that a pool of variants exists prior to the
introduction of a new selective pressure. A low frequency variant(s)
could quickly rise to high frequency because the selection
coefficient of this allele could be increased under the new
environmental conditions. Thus, diversity should offer a rapid
mechanism of evolution for the virus in an environment of
changing selective pressures. Alternatively, the low frequency
variants could simply represent non-functional genomes or be
reduced in frequency by negative selection. Data showing that the
frequency of variants in coding regions is significantly lower than
the frequency of variants in non-coding regions of the viral
genome (Table 5) are consistent with this explanation. Again, it is
possible that changing selective pressures could reverse this effect
and cause a change in frequency of these variants. Future
experiments should test the effect of changing selective pressures
on the frequency of pre-existing variants in the population.
Analysis of the sequence data revealed evidence of selection
within the viral populations. The results of the selective sweep
analysis(Figure6 and TableS5)areintriguinginthe contextofhost-
pathogen dynamics. Both UL123, encoding IE1, and UL83,
encoding pp65, were found to be within regions of selective sweeps
in one patient sample (U04). These proteins are demonstrated
targets of CD8
+ T cells in neonates with congenital infection [60]
and suggest an immune-mediated mechanism of selection. This is
the first evidence that known HCMV immune targets are also
targets of positive selection. The selective sweep analysis also
detected manyORFswithnoknownfunction.WhethertheseORFs
are under immune selection or are targets of positive selection for
other reasons, such as tropism or viral replication, is still unknown.
We found evidence of both positive and negative selection within
thegenomewhencomparinginterhostvariation.The resultssuggest
a model in which positive selection contributed to the divergence
across the HCMV species, but genetic stability of the viral species is
maintained with negative selection. Contrasting these long term
selectiveforces to the observed high level ofstandingvariation of the
intrahost populations may lead to a clearer interpretation of the
results. As mentioned above, the standing variation potentially
reduces the time of adaptation to a novel environment or pressure.
However, the negative selection acting on the variants may balance
this phenomenon and prevent deleterious mutations from reducing
the fitness of the overall HCMV species.
Two groups have recently reported using high throughput
sequencing to study HCMV from clinical material. In the report
by Cunningham et al [61], a major genome type sequence was
generated from clinical material. In contrast, Gorzer et al [44].
studied genetic populations at three loci. These approaches are
complementary to that presented here in which we sequenced
HCMV populations on genome wide scales. As compared to the
work of Cunningham et al, our study requires PCR amplification
to select for HCMV DNA, which produces more HCMV-specific
sequence data on a single sequencing run and greater depth of the
viral population. This increased sequencing depth allows for a
more accurate detection of minor variants within the population
(Table S1). However, the approach by Cunningham et al differs
from ours in that it allows for a more rapid sequencing of the
major genome type, thereby producing greater sequence infor-
mation about the HCMV species. In contrast, Gorzer et al
sequenced three loci of the HCMV genome to a greater depth
than our study, leading to higher levels of confidence in detecting
minor and rare variants. However, our use of a genome-wide
approach allows for unbiased detection of variability. As proof of
the power of this approach, a commonly studied variable ORF,
such as UL73 (gN), is in the lowest quintile for intrahost diversity,
while many of the ORFs with the highest intrahost diversity have
not been studied for variability. Therefore, a genome-wide study
can highlight loci for future studies using ultra-deep sequencing.
The results presented here suggest that diversity of DNA virus
populations should be studied more thoroughly to determine the
universality of the high level of variability. For example, in this
study we sampled HCMV populations from urine of congenitally
infected children. It is unknown if the genomic populations
sampled from urine are representative of the populations in other
compartments of the host. Also, the levels of replication during
congenital infections are very high, such that the diversity
observed in asymptomatic, adult hosts may be much lower due
to lower levels of replication and, therefore, fewer opportunities for
mutagenesis. Alternatively, the chance of co- or re-infection in
adults is much higher, possibly leading to more diverse
populations. Others have shown that Marek’s disease, another
herpesvirus, virus exists as a collection of mixed genotypes in
culture [62]. Thus, there is evidence of a similar phenomenon.
Whether high diversity, mixed genotype populations exist for other
herpesviruses or other dsDNA viruses outside of this family
remains to be seen.
Materials and Methods
Ethics statement
Clinical specimens were obtained from neonates with congenital
HCMV infection and de-identified prior to receipt by the
investigators. Specimens were gathered as part of a standard
clinical procedure. None of the investigators were involved in
specimen collection. The use of these specimens for research was
approved by the University of Massachusetts Medical School
Institutional Review Board (IRB Docket # 10778).
Patient population, collection of samples and cloned viral
DNA
Neonates within two weeks of age were diagnosed with
congenital HCMV infection at the request of their respective
Genome Wide Variability of HCMV
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Center clinical virology laboratory performed diagnostic virus
isolation. De-identified urine samples were then used for this study.
No clinical information about the infants was available. Samples
were stored at 280uC until DNA purification. DNA was purified
using a Qiagen Blood and Tissue Kit using the standard protocol.
HCMV BAC DNA has been described previously [40] and was
kindly provided by Tom Shenk (Princeton University). Isolation of
BAC DNA from E. coli strains was performed as described [63].
Amplification of HCMV DNA
We constructed a set of primer pairs spanning the entire
HCMV genome. Primers were designed to anneal to conserved
sites of the HCMV genomes, based on publicly available HCMV
sequences. These databases included the sequence of an HCMV
genome type (Strain 3157) that was produced directly from clinical
material without amplification [61]. Primer homology with this
strain supports the assertion that the chosen sites are found in wild
type strains, and will reduce primer mismatch bias. Amplicons
overlapped by ,100–500 bp such that sequence was generated at
primer binding sites from the adjoining amplicon. Using this
overlap data, primers were reevaluated and redesigned primers as
necessary, given that these new data potentially represent
thousands of unique HCMV genomes per experiment. Lastly,
primers were designed to have no or low homology to both human
sequence and any other possible contaminating DNA sources,
such as other herpesviruses or common human parasites and
commensal bacteria.
Most amplicons were ,6 kilobases (kb). Some were reduced to
3 kb if the original longer amplicon either gave no/weak
amplification or non-specific products as determined by Sanger
sequencing. Primer sequences used in this study are listed in Table
S8. For BAC and clinical sample PCR amplification, initial PCR
reactions were carried out using serially diluted templates to
determine the lowest quantity necessary for efficient amplification.
Quantitative PCR was performed using primers and probes
described previously [64] and it was determined that each reaction
contained ,1300 HCMV genomes. The conditions for PCR were
as follows: 1X PfuUltra II PCR buffer, 0.25 mM each dNTP
(NEB), .25 uM each primer (IDT DNA), 0.5 uL PfuUltra II
Polymerase (Agilent) and 1 M betaine. A touchdown PCR was run
on an Eppendorf Mastercycler ep gradient S with the following
program for all reactions: 98uC for 2 min, 5 cycles of 98uC for
30 s, 63uC (decreasing by 1u/cycle) for 30 s, 72uC for 2 min,
followed by 25 cycles of 98uC for 30 s, 58uC for 30 s and 72uC for
2 min, with a 10 min final extension at 72uC. All amplified
products were size-selected on agarose gels and gel purified.
Because insertions or deletions could produce amplicons of visibly
different sizes than expected, we used direct Sanger sequencing of
questionable amplicons to test for presence of the expected
HCMV sequence. After amplification of the HCMV genome, all
amplicons were quantified on a Nanodrop 1000, pooled in
equimolar proportions and used as substrate in Illumina
sequencing.
Illumina sequencing
The DNA in pooled amplicons was sheared by sonication on a
Sonic Dismembrator 550 (Fisher) until the median size was
,350 bp. The DNA library was prepared as stated previously
[65]. Briefly, DNA was end-repaired using the End-Repair
Enzyme Mix (NEB), and A-tailed using the ATP and Klenow
(exo
-) (NEB). Adapters with appropriate barcodes were ligated
onto the modified DNA ends. The library was then size selected on
a 2% agarose gel, to produce a library with a median size of
350 bp+/250 bp. The library was amplified with Illumina
primers (P/N 1003454) (www.illumina.com). Once prepared, the
libraries were combined in appropriate ratios and submitted for
paired-end sequencing on the Illumina GAII. A Toledo strain
amplicon set was included as an internal control for measuring
error rates.
BAC resequencing and development of methodology
HCMV BAC DNAs of the AD169 and Toledo strains were
PCR amplified and processed for sequencing as described above.
The barcoded DNAs were then sequenced on a single lane of the
Illumina GAII. Output sequences from the Illumina GAII were
first converted from Illumina FASTQ format to Sanger standard
FASTQ and were then separated based on barcode sequences,
which were subsequently trimmed before subsequent processing.
The sequences were then aligned to either the AD169 BAC
(GenBank # AC146999) or Toledo BAC (GenBank # AC146905)
using Novoalign (Novocraft). The alignment data were then
ported to MAQ through the Novo2MAQ utility (Novocraft) and
downstream analyses were performed with the MAQ software
suite [66]. The pileup output from the alignment was then
analyzed to call any mismatches between the sequence reads and
the reference genome. All mismatches from this output have an
associated basecall quality, mapping quality, local depth, number
of mismatch occurrences and mismatch frequency. The basecall
quality and mapping quality are calculated by the sequencing and
alignment software, respectively.
Development of variant filtering algorithm
We used HCMV-BACs as templates for PCR amplification and
paired-end sequencing on the Illumina GAII to develop an
algorithm that would reduce error. The output was 108 megabases
of HCMV sequence or the equivalent of approximately 466
HCMV genomes (Table 1). The data were aligned to the
appropriate reference genome using Novoalign and MAQ. Using
these data, we developed a variant filtering algorithm. This
algorithm has been designed to filter the mismatch output from the
alignment stage and aid in sorting ‘‘true’’ variants in the viral
population from those mismatches created by PCR or sequencing
errors. We produced in silico models of mixed viral populations in
which the AD169:Toledo ratio was 1:1, 1:10, 1:100, 1:200, and
1:1000. Thresholds for minimum basecall quality ($30), mapping
quality ($89), depth ($15), mismatch count ($3) and mismtach
frequency ($0.019) were found to minimize false positives. With
these conservative thresholds, we had a detection rate of up to
75%, suggesting that the variants detected in clinical samples will
under-represent the true level of variation in the populations.
However, the number of false positives was very low in these in
silico experiments even when the input minor genome was 1% of
the population (Table S1). Modeling of two genotype mixed
populations, like those represented in Table S1, illustrates a worst
case scenario for a false positive rate. In Table S1, there are two
types of variants: ‘‘true’’ variants, sourced from the minor genome
type, and errors resulting from PCR or sequencing. The absolute
level of true variants will be dependent on the number of minor
genome types; as the number of minor genome types increases, the
number of true variants also increases. The number of errors,
though, is a function of PCR and sequencing and should be
independent of the number of minor genome types. Thus, the
ratio of errors to true variants (the false positive rate) will decrease
as the number of minor genome types increases. In this modeling
experiment, there is only one minor genome type and thus, we are
recording the upper limit of false positive rates of a mixed genome
type population. From the Sanger dataset (Table 4), it was shown
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13 unique genotypes from 20 clones), not just one minor genotype.
Thus, this modeling experiment overestimates the actual false
positive rate of the clinical data.
It was possible that the relatively high G:C content of the
HCMV genome could alter error rates across the genome, and
should be addressed by the error filtering protocol. However, we
did not detect a relationship between error rates and G:C content
from the BAC resequencing data (data not shown). We did observe
an association between G:C content and depth, with reduced
depth at very low (20%) or very high (.80%) G:C content (data
not shown). This characteristic of the Illumina platform has been
documented previously [67]. We corrected for differences in depth
when analyzing the intrahost populations (Figure S5) so that
changes in depth associated with G:C content should not alter our
analyses.
Performance of quantitative high throughput
sequencing
To determine the quantitative capabilities of our methodology,
we combined Toledo and AD169 BAC DNA in ratios of 1:10 and
1:100 as templates for PCR amplification (with Toledo present as
the major genome) and then amplified two regions of the genome
using our PCR amplification technique. These two regions
represent ,6 kb of the HCMV genome and have a GC content
of 58%, approximately equal to the genome wide average of 57%.
In these regions, there are 118 sites of mismatch between the
Toledo and AD169 genomes. The amplification products were
processed and sequenced using the Illumina GAII platform and
the output was aligned to the Toledo genome. We ran the data
through our variant filtering algorithm to detect the minor variants
in the sequence population (i.e. AD169-derived sequence). Our
data revealed a 48% detection rate when the minor genome is
present as 10% of the PCR template and a 38% detection rate
when present as 1% (Table S9). The relatively low detection rate is
a consequence of the stringency of the filtering algorithm we
developed. The frequency of the minor variants detected in the
output sequence was approximately equal to their frequency in the
input DNA. These data show that this methodology is suitable for
detection and quantitative description of variants in populations.
Calling sample specific genome type of clinical samples
A schematic for calling genome types is shown in Figure S4.
The high throughput sequencing reads were initially aligned to
Merlin (Ref Seq ID: NC_006273). Output from this initial
alignment was used to call variants with frequency .0.5 at every
position of the genome because these variants were interpreted to
best represent the major allele of the sample. Sites that did not
have an allele with a frequency .0.5 were left as uncalled bases
(N), and were excluded from intrahost diversity measurements
since they represent tri- or quad-allelic sites. The high frequency
variants were incorporated into a sample specific genome type.
Reads that did not initially align were used as substrate for de novo
contiguous sequence (contigs) assembly using SHARCGS [68].
These contigs were then aligned to the sample specific genome
type using Geneious [69] and incorporated into the genome if
sequence identity was found. Using this strategy, we were able to
remove up to ,1 kb of uncalled bases from the genome type. The
sample specific genome type was used in another round of
alignment of the sample’s sequencing reads. With this strategy, we
observed a 1–6% increase in the number of aligned reads after this
round as compared to the initial alignment to Merlin. Because
more reads aligned, additional high frequency variants were
called. The high frequency variants were incorporated into the
sample specific genome type and again contigs were aligned to the
genome type. This process was repeated until no additional reads
aligned between rounds of building the sequence (usually 4 rounds
were required). At the end of the process, a single specific genome
type was created for each sample, which incorporates all high
frequency variants found within. It is unknown if the sample
specific genome type represents any single genome within the
sample because linkage information is lost from short read
sequencing. The sample specific genome type is a computational
tool that aids in the alignment of short reads, particularly when a
pre-existing reference sequence is unavailable or is divergent from
the sample.
Analysis of false positive rate of clinical samples
Variants were called from the clinical sequencing data or BAC
resequencing data through filtering with the variant caller
algorithm. All alignments used to generate the data were
normalized to an average depth of 200 genome equivalents. A
depth of 200 was chosen because the lowest depth of an included
dataset was ,200 (i.e., AD169 BAC resequencing), so the ceiling
was set to normalize across datasets. Mismatches from BAC
resequencing were assumed to be errors and mismatches from
clinical sequencing were assumed to be either errors or true
variants. Without filtering, BAC resequencing generated, on
average, 106,485 called mismatches and clinical sequencing
generated 116,594 mismatches (Figures S2A, S2C). Therefore,
we estimate a false positive rate in the unfiltered clinical data of
91.3% (106,485 of 116,594). However, filtering with the variant
caller reduced estimated false positives to 6.7% of the clinical
variants within populations (Figures S2B, S2D).
To determine the error rates of calling interhost polymorphisms
(frequency .0.5), a similar analysis of the BAC resequencing data
was undertaken. We determined that the error rate for calling
polymorphisms is 0.028%, or ,65 erroneous polymorphisms per
genome (Table S2). On average, interhost HCMV sequence data
contained .2300 polymorphisms per genome.
It should be noted that the error rate for calling interhost
polymorphisms is significantly lower than the error rate for calling
intrahost variants (0.028% vs. 6.7%). Intrahost variants must occur
at least 3 times as part of the filtering strategy. However, interhost
polymorphisms, because they are present at frequency .0.5 and
the minimum depth is 15, must occur more than 8 times to be
called. Because random errors generated by PCR or sequencing
will most likely be rare, the possibility of random errors occurring
$8 times and occurring in .50% of reads is low. Thus, a lower
percentage of errors are included in the interhost polymorphism
data then the intrahost variant data.
Measurement of positive selection in intrahost
populations
The genome wide intrahost variant data was analyzed using the
program SweepFinder (http://people.binf.ku.dk/rasmus/webpage/
sf.html), which implements the methods of Nielsen et al.[ 5 4 ]a n d
outputs the position, selection coefficient and composite likelihood
ratios (CLRs) of genomic regions. CLRs are measures of the
probability of a selective sweep within a genomic region. To
determine the significance of the data, 1000 simulations were
performed under a standard neutral model using the ms program
[70]. A set of simulations was run for each clinical sample
population, in which the number of segregating sites and value of
h (Watterson estimator) of the simulation equaled the corresponding
values calculated from the clinical samples. The simulation was then
processed with SweepFinder, and output from this analysis (Figure
Genome Wide Variability of HCMV
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the simulated outputs.
Clonal Sanger sequencing
ORFs were chosen for clonal Sanger sequence by selecting
candidate ORFs from each patient sample that displayed high
intrahost variability. All clonally sequenced regions were between
500–700 bp, such that variability data could be generated in a
single Sanger sequencing reaction. The regions were amplified
with the appropriate primers using the PCR protocol described
above, A-tailed with Kleno exo
- and dATP (NEB), and cloned into
the Strataclone cloning vector (Stratagene). For each ORF, 20
clones were selected at random and sequenced. As a control, a
500 bp region of Toledo-BAC was amplified and clonally
sequenced in the same manner. These data were then analyzed
in DnaSP [71] to determine nucleotide diversity (p) and genotype
distribution.
Statistical analyses
For analysis of the association of ORF function or kinetics with
intrahost nucleotide diversity or interhost dN/dS, a 1-factor
ANOVA analysis was performed. A Bonferroni correction for
multiple testing was carried out, where a significant p-value was
considered ,.05/K where K is the number of tests run per
dataset. A G-test was performed on the interhost dN/dS values
with the null hypothesis set as dN/dS=1. The McDonald-
Kreitman test was done using the web portal as described in [72],
which performs the analysis using a Jukes-Cantor correction for
divergence and the statistical analysis based on a 262 contingency
table. A neutral model was rejected if p,0.05. A Z-test was used to
determine the significance of the proportions of the mean diversity
of non-coding and coding variants. The distribution of variant
frequencies was analyzed by a two-tailed Mann-Whitney test.
Availability of data
Raw sequencing reads from Illumina sequencing are deposited
in the Sequence Read Archive (http://www.ncbi.nlm.nih.gov/
Traces/sra/sra.cgi). Major genome types generated from this
study are deposited in Genbank (http://www.ncbi.nlm.nih.gov/
genbank/index.html).
Supporting Information
Figure S1 Coverage of HCMV genome in previous sequencing
studies. The HCMV genome is depicted as a grey bar, with the
subdivisions of the genome shown above as black bars. The
coverage of the genome from previous sequencing studies is
depicted with blue bars, with each blue bar representing a
sequence study and the width of the bar being proportional to the
length of the sequenced region. Although some regions have been
sequenced in multiple studies (for example, UL55 (gB)), for the
purposes of this figure, we show the data from the study that
sequenced the largest region. The data used to construct this figure
are from [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16], which are listed
in Text S1.
Found at: doi:10.1371/journal.ppat.1001344.s001 (0.04 MB TIF)
Figure S2 Single nucleotide variant counts and frequencies as a
result of filtering. Variants were called from BAC resequencing or
clinical sequencing alignments normalized to an average depth of
250. A. Variants of all frequencies called from the two datasets
without filtering. B. Variants of all frequencies called from the two
datasets after filtering with the variant caller algorithm. C. Same as
A except that only variant frequencies from 0–0.2 are displayed.
D. Same as B except that only variant frequencies from 0–0.2 are
displayed.
Found at: doi:10.1371/journal.ppat.1001344.s002 (0.69 MB TIF)
Figure S3 Coverage map of HCMV genomes sequenced
directly from urine samples. HCMV was sequenced from urine
samples U01, U04 and U33 and the predicted coverage of the
genomes was calculated. The black bars show a one dimensional
representation of the genome, while the blue curve above is
indicative of both the coverage and quality of sequence data across
the genome. The presence of a blue curve indicates coverage of a
base and the height of the blue curve is proportional to the quality.
The major divisions of the HCMV genome are shown below the
graph.
Found at: doi:10.1371/journal.ppat.1001344.s003 (0.15 MB
TIF)
Figure S4 Flowchart of genome type calling and detection of
intrahost variants. Alignment of the high throughput sequence
data begins by using the HCMV reference sequence (Merlin, Ref
Seq ID: NC_006273). Mismatches between the reference
sequence and high throughput sequence reads are identified from
the alignment and data about all mismatches (depicted as C or T
in the figure) are outputted into a pileup file. The pileup files is
processed with a variant filter protocol that uses threshold values
for basecall quality, mapping quality, depth, mismatch frequency,
and the number of mismatch occurrences. Mismatches with
characteristics above these threshold values are outputted by the
variant filter. Mismatches from this filtering are either high
frequency (frequency .0.5, Red C) or low frequency (frequency
,0.5, Black T). The high frequency mismatches are interpreted to
be sample specific polymorphisms, and are incorporated into the
sample specific genome type. Additionally, unaligned reads are
used to build contiguous sequences (contigs) and are incorporated
into the sample specific genome type if showing homology to the
sample specific genome type. The sample specific genome type is
then used as the reference sequence for additional rounds of
alignment of the sequence reads. Again, high frequency polymor-
phisms are incorporated into the genome type, and contigs are
built and assembled onto the genome type. This process is
repeated until no additional high throughput sequence reads align
to the genome type. The genome type is exported to create the
final sample specific genome type (Blue line with incorporated C
polymorphism). Lastly, the high throughput sequence reads are
aligned to final genome type and variants are called to define the
intrahost variants of the viral population. For example, the black T
would be identified as an intrahost variant.
Found at: doi:10.1371/journal.ppat.1001344.s004 (1.16 MB TIF)
Figure S5 Scatter plot of ORF depth vs measured nucleotide
diversity. For all ORFs, the depth from high throughput sequence
data is compared to the calculated nucleotide diversity. The red
line represents the linear regression through the data. Equation for
linear regression: y=(1.153610
25)x+0.1872. A. The plot is shown
for all depth values on a logarithmic scale B. Same plot as in A but
only showing depth values between 15–1200, which are the values
selected for downstream analysis because the effect of depth on
calculated nucleotide diversity is ,.01%.
Found at: doi:10.1371/journal.ppat.1001344.s005 (0.45 MB TIF)
Figure S6 HCMV intrahost nucleotide diversity by ORF
expression kinetics. Intrahost nucleotide diversity was calculated
for each ORF of the HCMV genome. The ORFs were then
grouped by expression kinetics and average nucleotide diversity
was calculated across all three patients. Error bars represent the
95% confidence interval for the calculated mean. 1-factor
Genome Wide Variability of HCMV
PLoS Pathogens | www.plospathogens.org 12 May 2011 | Volume 7 | Issue 5 | e1001344ANOVA test for significance: p=0.0105 (not significant after
Bonferroni correction).
Found at: doi:10.1371/journal.ppat.1001344.s006 (2.34 MB TIF)
Figure S7 Unrooted phylogenetic trees of clonal Sanger
sequencing of HCMV populations. 3 ORFs per patient sample
were selected for clonal Sanger sequencing. The Sanger dataset
was then used to generate unrooted phylogenetic trees, using a
Jukes-Cantor model of substitution and a neighbor joining
method. Scale bars represent substitutions per site. Branch tips
are unlabeled except for those representing sequences from the
other patient samples, which are highlighted with red text.
Found at: doi:10.1371/journal.ppat.1001344.s007 (0.35 MB TIF)
Figure S8 Neutral simulations of HCMV populations. 1000
simulations of 3 populations using a standard neutral model were
generated via the ms program [24]. Theta and the number of
segregating sites in each simulation were matched to the
corresponding values from the clinical samples U01, U04 and
U33. The simulations were then analyzed using the Sweepfinder
program [25] and Composite Likelihood Ratios (CLRs) were
generated. The CLRs from the simulations were used to calculate
significance thresholds. The 5% significance thresholds for each
simulation set are shown as red, dotted lines.
Found at: doi:10.1371/journal.ppat.1001344.s008 (0.19 MB TIF)
Figure S9 HCMV interhost dN/dS by ORF expression kinetics.
Interhost dN/dS values were calculated for each ORF of the
HCMV genome. The ORFs were then grouped by expression
kinetics and average nucleotide diversity was calculated across all
three patients. Error bars represent the 95% confidence interval
for the calculated mean. 1-factor ANOVA test for significance:
p=0.1108.
Found at: doi:10.1371/journal.ppat.1001344.s009 (2.23 MB TIF)
Table S1 Mixed Population Modeling
Found at: doi:10.1371/journal.ppat.1001344.s010 (0.04 MB
DOC)
Table S2 Polymorphism Error Rate for BAC resequencing
Found at: doi:10.1371/journal.ppat.1001344.s011 (0.04 MB
DOC)
Table S3 Whole genome intrahost diversity data from clinical
samples
Found at: doi:10.1371/journal.ppat.1001344.s012 (0.44 MB PDF)
Table S4 Intrahost Nucleotide Diversity Select RNA Viruses
Found at: doi:10.1371/journal.ppat.1001344.s013 (0.08 MB
DOC)
Table S5 ORFs that overlap selective sweeps in the HCMV
genome
Found at: doi:10.1371/journal.ppat.1001344.s014 (0.06 MB PDF)
Table S6 Whole genome interhost polymorphism data from
patient samples
Found at: doi:10.1371/journal.ppat.1001344.s015 (0.27 MB PDF)
Table S7 Genome Wide McDonald-Kreitman Test
Found at: doi:10.1371/journal.ppat.1001344.s016 (0.19 MB
DOC)
Table S8 Primers used in this study to amplify HCMV Genome
Found at: doi:10.1371/journal.ppat.1001344.s017 (0.15 MB
DOC)
Table S9 Assay for Quantitative Capabilities of High Through-
put Sequencing Methodology
Found at: doi:10.1371/journal.ppat.1001344.s018 (0.05 MB
DOC)
Text S1 Supporting Figure Legends and References
Found at: doi:10.1371/journal.ppat.1001344.s019 (0.16 MB
DOC)
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